Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Capecitabine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention. Browse Capecitabine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
760
Shown on this page
12
Current sort
Recently updated
Therapy scope
Capecitabine
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Capecitabine. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 301–312 of 760 matching trials for Capecitabine.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

NCT00807859
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Tumors, Cancer, Locally Recurrent and Metastatic Breast Cancer, Metastases, Metastatic Cancer, Oncology, Solid Tumors, Tumors
Interventions
AMG 386 30 mg/kg, Paclitaxel and Trastuzumab, AMG 386 30 mg/kg, Capecitabine and Lapatinib, AMG 386 10 mgkg, Paclitaxel and Trastuzumab, AMG 386 10 mg/kg, Capecitabine and Lapatinib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
13
States / cities
Tucson, Arizona • Boca Raton, Florida • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

NCT03473639
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Cancer
Interventions
Entinostat, Capecitabine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Rochester, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Withdrawn Phase 2 Interventional

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

NCT00954876
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
capecitabine and cetuximab
Drug
Lead sponsor
Translational Genomics Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

NCT02218164
View directory record Official record
Conditions
Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
Interventions
Pegylated Interferon alpha-2b, Capecitabine, 5-FU
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT02394535
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7
Interventions
Capecitabine, Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Houston, Texas • League City, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

NCT05091528
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
Interventions
SBT6050, trastuzumab deruxtecan, tucatinib, trastuzumab, capecitabine
Drug
Lead sponsor
Silverback Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Completed No phase listed Observational

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00280761
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, 5-fluorouracil, Surgical Resection, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional Results available

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

NCT03930771
View directory record Official record
Conditions
Recurrent Pituitary Adenomas
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

NCT01497392
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dovitinib lactate, gemcitabine hydrochloride, capecitabine, laboratory biomarker analysis, enzyme-linked immunosorbent assay, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Study of CPI-100 in Patients With Advanced Tumors

NCT03781362
View directory record Official record
Conditions
Advanced Tumors
Interventions
CPI-100, Capecitabine
Drug
Lead sponsor
Coordination Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

NCT02574455
View directory record Official record
Conditions
Breast Cancer
Interventions
Sacituzumab govitecan, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
185
States / cities
Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 28, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

NCT02625610
View directory record Official record
Conditions
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Interventions
Avelumab, Oxaliplatin, 5-Fluorouracil, Leucovorin, Capecitabine, Best supportive care
Drug · Other
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
35
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 28, 2026, 5:40 AM EDT

About this Capecitabine clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Capecitabine.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Capecitabine.